Obatala Sciences’ Post

🌟 Novartis Partners with Generate in $1B Biotech Deal 🚀 Novartis and Generate forge $1B+ deal to innovate protein therapeutics using generative AI technology. This partnership aims to accelerate drug discovery and development. #Biotech #AI #HealthcareInnovation 🟢 This news is positive as it highlights a significant investment in the biotech industry, which could lead to breakthroughs in healthcare. Market outlook is optimistic with potential advancements in drug discovery and development. https://lnkd.in/d5VcRNdR

🌟 Discover the Future of Antibody Therapeutics at Xchange 2024! 🌟 We’re thrilled to feature Dr. Sundee Dees, Ph.D. , Senior Manager of Business Development at WuXi Biologics, as she takes the stage for an exclusive spotlight presentation at the upcoming Antibody Therapeutics Xchange in Maryland! 🎤💡 📅 Date: October 28, 2024 📍 Location: Marriott College Park, MD 🕑 Spotlight Presentation: 1:20 PM – 1:50 PM Dr. Dees, will be sharing groundbreaking insights in her talk, "Innovative Production and Engineering Strategies for Fab, ScFv & VHH". 🧬✨Whether you're addressing the challenges of antibody fragment development or fine-tuning production processes, this session is one you won’t want to miss! 💥 Key Highlights 🔑 🚀 Cutting-edge strategies for Fab, ScFv, & VHH production 🔍 Solving challenges in yield, purity, and stability 🏆 Tips to accelerate development with innovative molecular design 🤝 Plus, enjoy unparalleled networking with leaders in pharma and biotech! Secure your place now and connect with industry trailblazers like Dr. Dees,! 🎯 👉 Register Here: https://lnkd.in/gesVbeMS 💊 Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #AntibodyTherapeutics #Biopharma #Innovation #PharmaLeaders #Biotech #DrugDevelopment #AntibodyFragments #FabEngineering #ScFv #VHH #Therapeutics #Biologics #Immunotherapy #PharmaNetworking #AntibodyDiscovery #PharmaInnovation #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

🆕 Announcing New Xchange! 🗞️📰 We are thrilled to announce the launch of our brand-new digital magazine, News Xchange! 🎉 🌍 Stay ahead of the curve with the very latest company updates and industry news from the world of life sciences, pharma, and biotech. Whether you're passionate about Antibody Therapeutics, Immunotherapies, Advanced Therapies, Oligonucleotide Therapeutics, or the revolutionary impact of AI in Drug Discovery, News Xchange has you covered. 🥽🧪🔬 💡 Explore thought leadership articles, emerging trends, and expert insights, all designed to keep you informed and inspired. 🔗 Check out News Xchange here: https://lnkd.in/dp443drW Let’s shape the future of healthcare together! 🌟 #HubXchange #NewsXchange #PharmaNews #BiotechNews #LifeSciences #Innovation #AdvancedTherapies #AIInDrugDiscovery #Biopharma #HealthcareInnovation #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

Company Spotlight: BigHat Biosciences 🔦 Overview: BigHat Biosciences is a cutting-edge biotechnology company focused on designing safer and more effective antibody therapies. Leveraging the power of machine learning and synthetic #biology, BigHat aims to revolutionize the field of antibody discovery and engineering. -CEO - Mark DePristo -Co-founder and Chief Scientific Officer Peyton Greenside Key Technologies: -Milliner Platform: This proprietary platform integrates high-speed wet lab capabilities with advanced machine learning technologies, enabling the rapid synthesis, purification, and characterization of hundreds of recombinant antibodies in a single weekly workcell. -Machine Learning: BigHat uses state-of-the-art machine learning algorithms to optimize antibody design, ensuring greater safety and efficacy for patients. Recent Achievements: - BigHat has entered into several high-profile collaborations, including partnerships with AbbVie and Merck, to leverage artificial intelligence in the discovery of next-generation therapeutic antibodies. - The company recently raised $75 million in a #SeriesB funding round, led by Section 32, with participation from Amgen Ventures and Bristol Myers Squibb, among others. With its innovative approach and strong industry partnerships, BigHat Biosciences is well-positioned to make significant strides in the field of #antibody #therapeutics, offering hope for better treatments for a wide range of #diseases. If you wanna learn more about #BigHat Biosciences, check the link in the comments #Fierce15 #CRO #ClinicalData #Contractresearch #Lifesciences #Pharmaceuticals #Biotech

I’m very excited about the emergence of Archon Biosciences today!  We’ve been working 'in stealth' for over a year (James Lazarovits and George Ueda for 5+ years before that…!) to translate this incredible technology into powerful biotherapeutics unlike any other – both in structure and capability.    I remember the first time I read about computationally designed de novo proteins – yes, that’s a mouthful – and the Institute for Protein Design, University of Washington circa 2018 (after vaguely hearing about fold.it many years before that) – it seemed incredible.  Fast forward to last year when I met Jamie and George – I can confirm they are incredible (the science, the platform and the team – now Archon Bio!).  By the way, so did The Nobel Prize committee, which recognized computational protein design with the 2024 Nobel Prize in Chemistry (read more about that on our website at archon.bio)     Having started in biotechnology decades ago working on the amazing new promise of antibodies, I’m super excited about Archon’s potential. From previously ‘intractable’ MoAs (e.g. soluble autonomous agonism) to qualitatively differential potency, to significantly enhancing existing powerful antibody-based medicines – we’re excited to make it happen.     Finally, we’re interested in advancing medicines from this transformative (modular) platform to patients as fast as possible beyond our own pipeline – if you can imagine new possibilities with your antibody-based drugs, reach out and let’s chat!     #biotech #antibodies #AI #ComputationalProteinDesign #AbC #AntibodyCage 

🔬 Exciting Market Growth Alert: Patient-Derived Xenograft (PDX) Models Download PDF Brochure: https://lnkd.in/dUbTx7fm I'm thrilled to share insights on the remarkable expansion of the PDX model market, projected to nearly double from $426M (2023) to $839M by 2028, growing at an impressive 14.5% CAGR. Why this matters: - PDX models are revolutionizing drug development by offering unprecedented accuracy in preclinical testing - They're playing a crucial role in advancing personalized medicine - These models are becoming invaluable tools for biomarker discovery and disease diagnosis This growth spans across multiple segments: → Types: Mice and rat models → Methods: Subcutaneous and orthotopic implantation → Applications: From drug development to biobanking → End-users: Pharmaceutical companies, biotechs, and CROs 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: JSR Corporation, WuXi AppTec, The Jackson Laboratory, Charles River Laboratories, Taconic Biosciences, Oncodesign Precision Medicine - OPM, Inotiv, Inc. (US), Pharmatest Services, Hera BioLabs, EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH, XenTech, Urosphere, Altogen Labs, Abnova, Genesis Biotechnology Group, Biocytogen, Creative Animodel (US), BioDuro-Sundia, Aragen Life Sciences, Shanghai LIDE Biotech Co., Ltd. (China), Certis Oncology Solutions (US), InnoSer , IVRS AB, BEIJING IDMO Co.,Ltd, and Shanghai Chempartner Co. Ltd. (China). #Biotech #DrugDevelopment #PreclinicalResearch #PersonalizedMedicine #MarketGrowth #Healthcare #Innovation

Today, Archon Biosciences announced $20 million in seed financing led by Madrona and shared our vision for the future of drug development!    We’ve built a completely novel class of biologics, Antibody Cages (AbCs) designed to unlock powerful therapeutic targets beyond the reach of existing modalities and to better treat disease. AbCs integrate the unparalleled binding properties of antibodies into a boundless set of AI-generated nanostructures that have never existed in nature. Precise control over AbC structures provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold standard for biologic medicines.      Learn more in our press release here: https://lnkd.in/eTJxYNuk    To see AbCs in action and learn more about how Archon is applying generative protein design to improve human health, visit our website at https://www.archon.bio/     #biotech #antibodies #AI #ComputationalProteinDesign #AbC 

A big Pharma Aquisition in Austria... Whilst these Acquisition Plans have been no major secret, it has now been made official that Infrareal is expanding its presence in the Pharma and Biotech sector by acquiring the Takeda site in Orth an der Donau, Austria! 🏭 This 24-hectare site, featuring state-of-the-art facilities, specializes in gene and cell therapy and biologics. Infrareal’s vision is to further develop this site, attracting more companies in the Pharma and Life Sciences industries while prioritizing sustainability and decarbonization. In addition to Takeda, we've seen recent developments and CAPEX Investments from Boehringer Ingelheim, HOOKIPA Pharma Inc., and Biomay AG in Vienna over the past year. It's exciting to witness growth in the region, reinforcing Vienna's position as a key player in the European and global pharma markets, and while Vienna is nowhere near the size of biotech hubs like Basel, it’s great to see more cities striving to foster positive growth in the Life Sciences sector. More Info here: https://lnkd.in/dmbzQ7We #Pharma #Biotech #Sustainability #Infrareal #PharmaParkOrth #Vienna #LifeSciences #Innovation

Here's the optimized LinkedIn post version: Top Pharma Stocks to Watch in 2024: Investment Insights The pharmaceutical sector continues to be a dynamic investment landscape, offering compelling opportunities for strategic investors. This year's standout performers are characterized by innovative research, robust pipelines, and transformative healthcare solutions. Key areas driving pharmaceutical stock potential include: • Oncology and precision medicine breakthroughs • Advanced biotechnology developments • Emerging market expansions • Gene and cell therapy innovations • Vaccine technology advancements Investors should focus on companies demonstrating: - Strong research and development commitments - Diverse therapeutic portfolios - Strategic acquisition capabilities - Regulatory adaptability - Potential for scalable medical solutions While the sector presents significant growth potential, prudent investment requires thorough due diligence. Consider diversifying across established market leaders and high-potential innovative firms. The pharmaceutical industry isn't just about financial returns—it's about supporting groundbreaking medical advancements that can transform global healthcare outcomes. Stay informed, analyze carefully, and position your investment strategy strategically in this exciting sector. #PharmaInvestments #HealthcareTrends #InvestmentStrategy

//WEBINAR// Struggling to fast-track your preclinical research? Join our scientific experts as they discuss which strategies and resources can best help you minimize expensive preclinical roadblocks and obtain guidance on target to in vivo #pharmacology workflows, optimizing your path to clinic. https://okt.to/GQgOxR #invivo #biotech #drugdiscovery #preclinicial #startup